ijms-logo

Journal Browser

Journal Browser

Renal Dysfunction, Uremic Compounds, and Other Factors 3.0

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Toxicology".

Deadline for manuscript submissions: 31 October 2024 | Viewed by 639

Special Issue Editors


E-Mail Website
Guest Editor
Department of Internal Medicine D, University Hospital Muenster, 48149 Münster, Germany
Interests: nephrology; endothelial dysfunction; cell biology; angiogenesis; risk factors
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Internal Medicine D, University Hospital Muenster, 48149 Münster, Germany
Interests: nephrology; dialysis; cardiorenal syndrome; angiogenesis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue is a continuation of our previous successful Special Issue "Renal Dysfunction, Uremic Compounds, and Other Factors" (https://www.mdpi.com/journal/ijms/special_issues/Renal_Uremic).

When the kidneys fail, many endogenous substances accumulate in the circulation due to decreased renal clearance and increased production. These substances, including uremic toxins, inflammatory mediators, modified biomolecules, and growth factors, cause a complex local and systemic derangement in metabolism and signaling, affecting nearly all body organs and systems. This occurs not only in the setting of chronic and end-stage renal disease but also due to acute kidney injury. Therefore, identifying uremic compounds and other factors that have a biological effect on cells and tissues is necessary to understand the mechanisms linking kidney disease and other organs and build up better therapeutic strategies.

This Special Issue explores soluble mediators in renal disease (acute and chronic kidney diseases). It includes original articles and review papers reporting on aspects related to their biological effects, disease progression, involvement in inter-organ communication, and therapy. Potential topics include, but are not limited to, the search for new factors/biomarkers, the toxicity of uremic compounds, post-translational modification of proteins and peptides, molecular mechanisms of action, inflammation, the gut microbiome, organ cross-talk, and new techniques and analytical methods for the measurement and detection of soluble compounds or their (toxic) effects.

Dr. Giovana S. Di Marco
Prof. Dr. Marcus Brand
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • renal dysfunction
  • acute kidney disease
  • chronic kidney disease
  • soluble mediators
  • uremic toxins
  • disease progression
  • organ cross-talk
  • therapy
  • new techniques

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

13 pages, 696 KiB  
Review
Updates on C3 Glomerulopathy in Kidney Transplantation: Pathogenesis and Treatment Options
by Giulia Bartoli, Andrea Dello Strologo, Giuseppe Grandaliano and Francesco Pesce
Int. J. Mol. Sci. 2024, 25(12), 6508; https://doi.org/10.3390/ijms25126508 - 13 Jun 2024
Viewed by 412
Abstract
C3 glomerulopathy is a rare disease, characterized by an abnormal activation of the complement’s alternative pathway that leads to the accumulation of the C3 component in the kidney. The disease recurs in more than half of kidney transplant recipients, with a significant impact [...] Read more.
C3 glomerulopathy is a rare disease, characterized by an abnormal activation of the complement’s alternative pathway that leads to the accumulation of the C3 component in the kidney. The disease recurs in more than half of kidney transplant recipients, with a significant impact on graft survival. Recurrence of the primary disease represents the second cause of graft loss after organ rejection. In C3 glomerulopathy, there are several risk factors which can promote a recurrence during transplantation, such as delayed graft function, infection and monoclonal gammopathy. All these events can trigger the alternative complement pathway. In this review, we summarize the impact of C3 glomerulopathy on kidney grafts and present the latest treatment options. The most widely used treatments for the disease include corticosteroids and mycophenolate mofetil, which are already used chronically by kidney transplant recipients; thus, additional treatments for C3 glomerulopathy are required. Currently, several studies using anti-complement drugs (i.e., eculizumab, Ravalizumab, avacopan) for C3 glomerulopathy in kidney transplant patients are ongoing with encouraging results. Full article
(This article belongs to the Special Issue Renal Dysfunction, Uremic Compounds, and Other Factors 3.0)
Show Figures

Figure 1

Back to TopTop